UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed	by the R	egistrant ⊠	Filed by a Party other than the Registrant \square	
Checl	k the app	propriate box:		
	Confid Defini Defini	reliminary Proxy Statement onfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) efinitive Proxy Statement efinitive Additional Materials oliciting Material Pursuant to §240.14a-12		
			FULCRUM THERAPEUTICS, INC. (Name of registrant as specified in its charter)	
			(Name of person(s) filing proxy statement, if other than the registrant)	
Paym	ent of Fi	ling Fee (Check the	e appropriate box):	
			elow per Exchange Act Rules 14a-6(i)(1) and 0-11. s of securities to which transaction applies:	
	(2)	Aggregate numbe	er of securities to which transaction applies:	
	(3)		other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the lated and state how it was determined):	
	(4)	Proposed maximu	ım aggregate value of transaction:	
	(5)	Total fee paid:		
	Check	box if any part of	preliminary materials. the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was the previous filing by registration statement number, or the Form or Schedule and the date of its filing. ly Paid:	
	(2)	Form, Schedule o	r Registration Statement No.:	
	(3)	Filing Party:		
	(4)	Date Filed:		



FULCRUM THERAPEUTICS, INC. Important Notice Regarding the **Availability of Proxy Materials**

For the Stockholders Meeting to be held on June 9, 2021

For Stockholders as of April 12, 2021

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy statement and the annual report and to register to attend the virtual annual meeting, go to: www.proxydocs.com/FULC

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. We have chosen to use these procedures for our Annual Meeting and need YOUR participation.

CONTROL NUMBER



For a convenient way to VIEW proxy materials and VOTE go to www.proxydocs.com/FULC

Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions

Proxy Materials Available to View or Receive: Annual Report and Proxy Statement

If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 28, 2021.

To order paper materials, use one of the following methods.



INTERNET

www.investorelections.com/FULC

control number located in the shaded box above.

TELEPHONE (866) 648-8133



paper@investorelections.com

"If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions CR other inquiries should be included with your e-mail requesting material. When requesting via the Internet or telephone you will need the 12 digit

Fulcrum Therapeutics, Inc. Notice of Annual Meeting

Meeting Type: Annual Meeting of Stockholders

For holders as of: April 12, 2021 Date: Wednesday, June 09, 2021 Time: 09:00 AM, Eastern Time

Place: Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/FULC for more details.

You must register to attend the annual meeting online and participate at www.proxydocs.com/FULC

SEE REVERSE FOR FULL AGENDA

Fulcrum Therapeutics, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR EACH OF THE NOMINEES IN PROPOSAL 1 AND FOR PROPOSAL 2.

PROPOSAL

- To elect three Class II directors named below to a 3-year term expiring at the 2024 annual meeting of stockholders.
 - 1.01 James Collins
 - 1.02 James Geraghty
 - 1.03 Bryan Stuart
- To ratify the appointment of Einst & Young as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2021.

Note: To consider and act upon such other business as may properly come before the meeting or any adjournment thereof.

Upon completing your registration, you will receive a confirmation email that your registration was successful. On the day of the meeting, you will receive further instructions via email, including your unique links that will allow you access to the meeting, vote online during the meeting and will also permit you to submit questions during the meeting. Please be sure to follow instructions found on your Proxy Card, this Notice and/or Voting Authorization Form and subsequent instructions that will be delivered to you via email.